Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide.
Keith M SkubitzEvidio Domingo-MusibayBruce R LindgrenEdward Y ChengPublished in: Cancers (2022)
Several studies have reported an association between levels of circulating blood cells, in particular the neutrophil to lymphocyte ratio (absolute neutrophil count (ANC)/absolute lymphocyte count (ALC)) and outcomes in patients with cancer. In the current study, the association between lymphocyte, neutrophil, monocyte, and platelet counts and survival was examined in a prospective trial of preoperative pegylated-liposomal doxorubicin and ifosfamide for high-grade soft-tissue sarcomas. A statistically significant association between overall survival, but not progression free-survival, was observed with the ANC/ALC ratio at a cutoff value of ≥2 and a statistically significant trend using a cutoff of ≥5. Our results suggest that a balance between the lymphocyte count and the number of circulating myeloid cells that can suppress lymphocyte function may be predictive of survival in patients with soft-tissue sarcomas. Future research should therefore examine the role of lymphocyte-myeloid cell balance in sarcoma biology.
Keyphrases
- peripheral blood
- high grade
- free survival
- soft tissue
- low grade
- induced apoptosis
- bone marrow
- cell cycle arrest
- clinical trial
- dendritic cells
- study protocol
- drug delivery
- randomized controlled trial
- acute myeloid leukemia
- phase ii
- type diabetes
- cell death
- single cell
- signaling pathway
- insulin resistance
- cancer therapy
- skeletal muscle
- endothelial cells
- double blind